Hutchmed (China) Limited

Transaction in Own Shares • Mar 10, 2021

National Storage Mechanism | Additional information

RNS Number : 6321R

Hutchison China Meditech Limited

10 March 2021

Vesting of awards under the Long Term Incentive Plan

Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, March 10, 2021: Hutchison China MediTech Limited ("HUTCHMED") (Nasdaq/AIM: HCM) announces that following the announcement of the 2020 annual results of HUTCHMED on March 4, 2021, 2,656 American depositary shares ("ADS") granted under the Long Term Incentive Plan ("LTIP") on March 15, 2017 to Dr Weiguo Su were vested on March 9, 2021.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Dr Weiguo Su

2

Reason for the notification

a)

Position/status

Executive Director and Chief Scientific Officer

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hutchison China MediTech Limited

b)

LEI

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

ADS each representing five Ordinary Shares of US$0.10

ADS ISIN: US44842L1035

b)

Nature of the transaction

Vesting of awards granted on March 15, 2017 under HUTCHMED's LTIP

c)

Price(s) and volume(s)

Price(s)	Volume(s)
Nil	2,656 ADS

d)

Aggregated information

-	Aggregated volume
-	Price

N/A

e)

Date of the transaction

2021-03-09

f)

Place of the transaction

Outside a trading venue

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.  It has advanced ten cancer drug candidates from discovery into clinical studies around the world and has an extensive commercial infrastructure in its home market of China.  For more information, please visit: www.hutch-med.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995.  Forward-looking statements involve risks and uncertainties.  Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  For further discussion of these and other risks, see HUTCHMED's filings with the U.S. Securities and Exchange Commission and on AIM.  HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

Investor Enquiries
Mark Lee, Senior Vice President	+852 2121 8200
Annie Cheng, Vice President	+1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, Solebury Trout	+1 (917) 570 7340 (Mobile) [email protected]
Europe - Ben Atwell / Alex Shaw, FTI Consulting	+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) [email protected]
Asia - Joseph Chi Lo / Zhou Yi, Brunswick	+852 9850 5033 (Mobile), [email protected] / +852 9783 6894 (Mobile), y[email protected]
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited	+44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEANDNEDPFEEA